EPO and pulmonary arterial hypertension: The stabilizing HIF-1α can also induce numerous physiological responses to compensate for the decreased tissue oxygen supply, including the production of erythropoietin (EPO), which can cause an increase in hemoglobin, may result in secondary erythrocytosis and pulmonary hypertension [58].